Novo Nordisk's weight loss elixir trims cardiovascular risk by 20%

Novo Nordisk's Wegovy is causing ripples in the healthcare industry. By safeguarding heart health, the drug is propelling a bold shift in obesity treatments and beyond.

Bottom line

Wegovy's heart-protective effects, revealed in a large international study, could reshape obesity treatments and lead to insurance coverage, benefiting Novo Nordisk (part of our Biotech360 strategy).

Novo Nordisk and Lilly's recent breakthroughs in cardiovascular and liver conditions, while boosting their stock values, have triggered significant sell-offs in the healthcare sector due to the perceived impact on chronic disease markets.

While we applaud progress against obesity, uncertainties still linger about long-term drug adherence to weight-loss medications and their repercussions. We believe that the influence of these drugs on the medical device sector is misconstrued, and this unwarranted market decline represents a favorable entry opportunity in some stocks, such as Shockwave Medical and Dexcom (both in our Bionics strategy). 

This article is available to logged users.
Sign in or request a login.



This report has been produced by the organizational unit responsible for investment research (Research unit) of atonra Partners and sent to you by the company sales representatives.

As an internationally active company, atonra Partners SA may be subject to a number of provisions in drawing up and distributing its investment research documents. These regulations include the Directives on the Independence of Financial Research issued by the Swiss Bankers Association. Although atonra Partners SA believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report.

The information contained in these publications is exclusively intended for a client base consisting of professionals or qualified investors. It is sent to you by way of information and cannot be divulged to a third party without the prior consent of atonra Partners. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such.

Past performance is not indicative or a guarantee of future results. Investment losses may occur, and investors could lose some or all of their investment. Any indices cited herein are provided only as examples of general market performance and no index is directly comparable to the past or future performance of the Certificate.

It should not be assumed that the Certificate will invest in any specific securities that comprise any index, nor should it be understood to mean that there is a correlation between the Certificate’s returns and any index returns.

Any material provided to you is intended only for discussion purposes and is not intended as an offer or solicitation with respect to the purchase or sale of any security and should not be relied upon by you in evaluating the merits of investing inany securities.